{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:17:48Z","timestamp":1771877868943,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR UCLH Biomedical Research Centre"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.08.036","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T18:46:13Z","timestamp":1507401973000},"page":"135-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"J.","family":"Edeline","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-F.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Campillo-Gimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-T.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Faluyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.08.036_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2017.08.036_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"EASL, EORTC","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl. 7","key":"10.1016\/j.ejca.2017.08.036_bib3","doi-asserted-by":"crossref","first-page":"vii41","DOI":"10.1093\/annonc\/mds225","article-title":"Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Verslype","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2017.08.036_bib4","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1093\/annonc\/mdt055","article-title":"Sorafenib: from literature to clinical practice","volume":"24","author":"Di Marco","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2017.08.036_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2017.08.036_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510280322","article-title":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators","volume":"28","year":"1998","journal-title":"Hepatol Balt Md"},{"key":"10.1016\/j.ejca.2017.08.036_bib7","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1002\/hep.1840040703","article-title":"Prognosis of primary hepatocellular carcinoma","volume":"4","author":"Okuda","year":"1984","journal-title":"Hepatol Balt Md"},{"key":"10.1016\/j.ejca.2017.08.036_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2013the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.036_bib9","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2017.08.036_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Grouped'Etudeet de Traitement du Carcinome H\u00e9patocellulaire","volume":"31","author":"Chevret","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jhep.2015.10.029","article-title":"Prognosis of hepatocellular carcinoma: assessment of eleven staging systems","volume":"64","author":"Liu","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatol Balt Md"},{"key":"10.1016\/j.ejca.2017.08.036_bib13","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann Oncol Off J EurSoc Med Oncol ESMO"},{"key":"10.1016\/j.ejca.2017.08.036_bib14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2014.07.002","article-title":"How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma","volume":"61","author":"Hucke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2013.08.022","article-title":"The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE","volume":"60","author":"Hucke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2014.11.014","article-title":"Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process","volume":"62","author":"Adhoute","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib17","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejca.2017.08.036_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MEG.0000000000000558","article-title":"Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study","volume":"28","author":"Adhoute","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib19","first-page":"1","article-title":"Prognostic scoring models for patients undergoing sorafenib treatment for advanced stage hepatocellular carcinoma in real-life practice","author":"Choi","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.036_bib20","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1111\/hepr.12480","article-title":"Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma","volume":"45","author":"Takeda","year":"2015","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.ejca.2017.08.036_bib21","article-title":"A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for hepatocellular carcinoma","author":"Edeline","year":"2016","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.ejca.2017.08.036_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hep.25950","article-title":"Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system","volume":"57","author":"Hsu","year":"2013","journal-title":"Hepatol Balt Md"},{"key":"10.1016\/j.ejca.2017.08.036_bib23","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-014-4151-2","article-title":"Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis","volume":"22","author":"Hsu","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T22:26:03Z","timestamp":1603059963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917312716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":23,"alternative-id":["S0959804917312716"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}